Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Blood

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Blood|January 31, 2015
Blind men and an elephantShaji Kumar
Blood|April 26, 2003
Expression of CD52 on plasma cells in plasma cell proliferative disordersShaji Kumar, Teresa K Kimlinger, John A Lust, et al.
Blood|July 31, 2009
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Mamta Gupta, Stephen M Ansell, Anne J Novak, et al.
Blood|July 19, 2011
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myelomaRishi K Wadhera, Robert A Kyle, Dirk R Larson, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
Blood|January 22, 2010
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide inductionMorie A Gertz, Shaji Kumar, Martha Q Lacy, et al.
Blood|October 22, 2024
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detectionAlissa Visram, Dirk Larson, Aaron Norman, et al.
Blood|March 28, 2012
Progression in smoldering Waldenstrom macroglobulinemia: long-term resultsRobert A Kyle, Joanne T Benson, Dirk R Larson, et al.
Blood|July 31, 2009
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaCheng E Chee, Shaji Kumar, Dirk R Larson, et al.
Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Blood|January 31, 2015
Blind men and an elephantShaji Kumar
Blood|April 26, 2003
Expression of CD52 on plasma cells in plasma cell proliferative disordersShaji Kumar, Teresa K Kimlinger, John A Lust, et al.
Blood|July 31, 2009
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Mamta Gupta, Stephen M Ansell, Anne J Novak, et al.
Blood|July 19, 2011
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myelomaRishi K Wadhera, Robert A Kyle, Dirk R Larson, et al.
Blood|May 8, 2004
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionShaji Kumar, Thomas E Witzig, Michael Timm, et al.
Blood|January 22, 2010
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide inductionMorie A Gertz, Shaji Kumar, Martha Q Lacy, et al.
Blood|October 22, 2024
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detectionAlissa Visram, Dirk Larson, Aaron Norman, et al.
Blood|March 28, 2012
Progression in smoldering Waldenstrom macroglobulinemia: long-term resultsRobert A Kyle, Joanne T Benson, Dirk R Larson, et al.
Blood|July 31, 2009
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaCheng E Chee, Shaji Kumar, Dirk R Larson, et al.
Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Pageof 5